Statin Therapy in Geriatric Patients

Introduction to Statin Guidelines

The American College of Cardiology recommends continuing or initiating moderate-to-high intensity statin therapy in geriatric patients with established cardiovascular disease, regardless of age, as efficacy is well-documented even in the very elderly 1

For patients ≤75 years with established ASCVD, high-intensity statin therapy is recommended 1
For patients >75 years with established ASCVD, moderate-intensity statins are preferred over high-intensity regimens 1
The American College of Cardiology recommends continuing statins if already established before age 75, as discontinuation shows no rebound adverse effects but loses protective benefit 1

For patients 65-75 years with diabetes, hypertension, or calculated 10-year ASCVD risk ≥7.5%, the American College of Cardiology recommends initiating moderate-intensity statin therapy (Class I recommendation) 2, 1
Meta-analyses demonstrate that statins reduce MI risk by 40% and stroke by 24% in patients ≥65 years 2, 1
For patients 76-84 years, the UK National Institute for Health and Care Excellence provides strong recommendations for statin initiation, recommending atorvastatin 20 mg based on QRISK2 risk assessment 2, 1

For patients with LDL-C ≥190 mg/dL at any age, the American College of Cardiology recommends initiating high-intensity statin therapy regardless of other risk factors 5
For patients ≥85 years, consider atorvastatin 20 mg to reduce non-fatal MI risk if functional status is good, no cognitive decline exists, and life expectancy exceeds 3-5 years 2, 1
The American Diabetes Association recommends moderate-intensity statin therapy for geriatric patients with diabetes ≥75 years, regardless of baseline LDL-C levels 1

Start with atorvastatin 10-20 mg or rosuvastatin 5-10 mg (moderate-intensity) in patients >75 years 1
Avoid high-intensity statins in patients >75 years unless treating secondary prevention in patients ≤75 years who tolerate therapy well 1

Assess LDL-C levels 4-12 weeks after statin initiation or dose adjustment 1
Age ≥65 years is an independent risk factor for statin-induced myopathy; heightened vigilance is required 1

Only 8% of patients in statin trials were >75 years at enrollment, creating a significant evidence gap 1
Do not focus solely on cholesterol levels; assess overall cardiovascular risk including age, hypertension, diabetes, and smoking 3
Do not withhold statins in elderly patients with established ASCVD based on age alone; secondary prevention benefits persist 1